VolitionRx 8-K: Administrative Update, NYSE American Listing Confirmed
Ticker: VNRX · Form: 8-K · Filed: Jan 2, 2024 · CIK: 93314
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, exchange-listing
TL;DR
**VNRX filed an administrative 8-K, no major news for traders.**
AI Summary
VolitionRx Limited filed an 8-K on January 2, 2024, reporting an "Other Events" item from December 29, 2023. This filing primarily updates administrative information, confirming its registration on the NYSE American, LLC under the ticker VNRX for its Common Stock, par value $0.001 per share. For investors, this filing is largely administrative and doesn't signal any immediate operational or financial changes, meaning it has minimal direct impact on the stock's valuation or future prospects.
Why It Matters
This filing is mostly administrative, confirming basic company details and its stock exchange listing, which means it has little direct impact on the company's financial health or stock price.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not disclose any events that would introduce new financial or operational risks.
Analyst Insight
A smart investor would note this filing is purely administrative and does not warrant any immediate action regarding buying, selling, or holding VNRX stock, as it contains no new material financial or operational information.
Key Numbers
- $0.001 — Par Value per Share (The par value of VolitionRx Limited's Common Stock.)
Key Players & Entities
- VolitionRx Limited (company) — the registrant filing the 8-K
- NYSE American, LLC (company) — the exchange where VolitionRx's common stock is registered
- $0.001 (dollar_amount) — par value per share of common stock
- December 29, 2023 (date) — date of the earliest event reported in the 8-K
- January 2, 2024 (date) — date the 8-K was filed
FAQ
What is the primary purpose of this 8-K filing by VolitionRx Limited?
The primary purpose of this 8-K filing is to report 'Other Events' as of December 29, 2023, and to confirm administrative details, including the company's registration on the NYSE American, LLC.
On which stock exchange is VolitionRx Limited's Common Stock registered?
VolitionRx Limited's Common Stock, with a par value of $0.001 per share, is registered on the NYSE American, LLC, as stated in the filing under 'Name of Each Exchange on which Registered'.
What is the ticker symbol for VolitionRx Limited's Common Stock?
The ticker symbol for VolitionRx Limited's Common Stock is VNRX, as indicated under 'Trading Symbol(s)' in the filing.
What was the 'Date of earliest event reported' in this 8-K filing?
The 'Date of earliest event reported' in this 8-K filing was December 29, 2023.
Does this 8-K filing indicate any changes in VolitionRx Limited's business operations or financial condition?
No, this 8-K filing primarily contains administrative information and does not indicate any changes in VolitionRx Limited's business operations or financial condition; it is filed under 'Other Events' and confirms existing registration details.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 12.8 · Accepted 2024-01-02 08:00:25
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
- $13.0 million — onRx Limited (the " Company ") received $13.0 million in milestone payments from Heska Corpor
Filing Documents
- vnrx_8k.htm (8-K) — 22KB
- 0001477932-24-000002.txt ( ) — 141KB
- vnrx-20231229.xsd (EX-101.SCH) — 6KB
- vnrx-20231229_lab.xml (EX-101.LAB) — 14KB
- vnrx-20231229_cal.xml (EX-101.CAL) — 1KB
- vnrx-20231229_pre.xml (EX-101.PRE) — 9KB
- vnrx-20231229_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 29, 2023, VolitionRx Limited (the " Company ") received $13.0 million in milestone payments from Heska Corporation ("Heska"), pursuant to the License and Supply Agreement entered into on March 28, 2022, between Belgian Volition SRL, a wholly-owned subsidiary of the Company, and Heska. The milestone payments arose from the successful assay transfer of the Nu.Q Vet Cancer Test onto Heska's Element i+ Immunodiagnostic Analyzer, a point of care platform for use by veterinarians and designated the "Heska Nu.Q Vet Canine Cancer Screen and Monitor" test. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: January 2, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 3